Ovarielles Überstimulationssyndrom-update - Teil 1

Inzidenz und Pathogenese

Literatur

• 1 Di Carlo C, Bruno P, Cirillo D, Morgera R, Pellicano M, Nappi C. Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome.  Hum Reprod. 1997;  12 2115-2117
• 2 Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart and Costagliola G S. Brief report: ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor.  N Engl J Med. 2003;  349 760-766
• 3 Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).  Hum Reprod Update. 2003;  9 77-96
• 4 Deutsches IVF-Register . www.deutsches-ivf-register.de .  Jahrbuch. 2002;  1-32
• 5 Ben-Chetrit A, Eldar-Geva T, Gal M, Huerta M, Mimon T, Algur N, Diamant Y Z, Margalioth E J. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial.  Hum Reprod. 2001;  16 1880-1884
• 6 Bellver J, Muñoz E A, Ballesteros A, Soares S R, Bosch E, Simón C, Pellicer A, Remohí J. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.  Hum Reprod. 2003;  18 2283-2288
• 7 Ludwig M, Gembruch U, Bauer O, Diedrich K. Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS.  Hum Reprod. 1998;  13 2082-2087
• 8 Schenker J G. Prevention and treatment of ovarian hyperstimulation.  Hum Reprod. 1993;  8 653-659
• 9 Schneider K TM. Wissenschaftlich begründete Geburtshilfe.  Gynäkologe. 2003;  35 840-844
• 10 Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!.  Hum Reprod. 2003;  18 1557-1558
• 11 Kissler S, Siebzehnrübl E, Kaufmann M. Von der Pathophysiologie und Prävention des ovariellen Überstimulationssyndroms (OHSS) bis zur stadiengerechten Therapie.  Geburtsh Frauenheilk. 2002;  62 1155-1161
• 12 Schubert J, Merz M, Distler W. Das ovarielle Überstimulationssyndrom.  Gynäkologe. 2002;  35 363-371
• 13 Keck C, Neulen J, Behre H M, Breckwoldt M. Endokrinologie, Reproduktionsmedizin, Andrologie. 2. Aufl. Stuttgart; Thieme Verlag 2002
• 14 Geisthövel F, Christ L, Haibt L, Ochsner A. Assisted reproductive techniques: risks, contraindications, prognostic factors, therapeutic strategies.  Andrologia. 2003;  35 168-169
• 15 Forman R G. Severe OHSS - an unacceptable price.  Hum Reprod. 1999;  14 2687-2688
• 16 Golan A, Ron-el R, Herman R, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome an update review.  Obst Gynecol Surv. 1989;  44 430-440
• 17 Kaiser U B. The pathogenesis of the ovarian hyperstimulation syndrome.  N Engl J Med. 2003;  349 729-732
• 18 Vasseur C, Rodien P, Beau I, Desroches A, Gérard C, de Poncheville L, Chaplot S, Savagner F, Croué A, Mathieu E, Lahlou N, Descamps P, Misrahi M. Brief report: a chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome.  N Engl J Med. 2003;  349 753-759
• 19 Tozer A J, Al-Shawaf T, Gillott C MY, Lower A M, Grudzinskas J G. Excessive follicular response to controlled ovarian stimulation in a woman with menopausal FSH levels: Case report.  Hum Reprod. 2004;  19 107-109
• 20 Delbaere A, Smits G, Olatunbosun O, Pierson R. Vassart G, Costagliola S. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?.  Hum Reprod. 2004;  DOI: 10.1093/humrep/deh124,1-4
• 21 Lyons C A, Wheeler C A, Frishman G N, Hackett R J, Seifer D B, Haning Jr. RV early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.  Hum Reprod. 1994;  9 792-799
• 22 Neulen J. Das ovarielle Überstimulationssyndrom Reproduktionsmedizin.  . 2001;  17 149-152
• 23 McElhinney B, Ardill J, Caldwell C, Lloyd F, McClure N. Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others?.  Hum Reprod. 2002;  17 1548-1553
• 24 Wang T H, Horng S G, Chang C L, Wu H M, Tsai Y J, Wang H S, Soong Y K. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.  J Clin Endocrinol Metab. 2002;  87 3300-3308
• 25 Meldrum D R. Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome.  Fertil Steril. 2002;  78 1170-1171
• 26 Orvieto R. Prediction of ovarian hyperstimulation syndrome: Challenging the estradiol mythos.  Hum Reprod. 2003;  18 665-667
• 27 Ito M, Harada T, Iwabe T, Tanikawa M, Terakawa N. Cytokine levels in a patient with severe ovarian hyperstimulation syndrome before and after the ultrafiltration and reinfusion of ascitic fluid.  J Ass Reprod Gen. 2000;  17 118-120
• 28 Abramov Y, Schenker J G, Lewin A, Kafka I, Jaffe H, Barak V. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndome.  Fertil Steril. 2001;  76 51-57
• 29 Levinsohn-Tavor O, Friedler S, Schachter M, Raziel A, Strassburger D, Ron-El R. Coasting - what is the best formula?.  Hum Reprod. 2003;  18 937-940
• 30 Ludwig M, Bauer O, Lopens A, Jelkmann W, Diedrich K. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome.  Hum Reprod. 1998;  13 30-32
• 31 Artini P G, Monti M, Fasciani A, Battaglia C, D'Ambrogio G, Genazzani A R. Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 2002;  101 169-174
• 32 Mathur R, Hayman G, Bansal A, Jenkins J. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception.  Fertil Steril. 2002;  78 1154-1158
• 33 Hammadeh M E, Fischer-Hammadeh C, Hofmeister H, Huebner U, Georg T, Rosenbaum P, Schmidt W. Fibroblast growth factor (FGF), intracellular adhesion molecule (sICAM-1) level in serum and follicular fluid of infertile women with polycystic ovarian syndrome, endometriosis and tubal damage, and their efect on ICSI outcome.  AJRI. 2003;  50 124-130
• 34 Gokmen O, Ugur M, Ekin M, Keles G, Turan C, Oral H. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study.  Eur J Obstet Gynecol Reprod Biol. 2001;  96 187-192
• 35 Jäger W, Diedrich K, Wild L. Elevated levels of CA 125 in serum of patients suffering from ovarian overstimulation syndrome.  Fertil Steril. 1987;  48 675-678
• 36 Delvigne A, Kostyla K, De Leener A, Lejeune B, Cantiniaux B, Bergmann P, Rozenberg S. Metabolic characteristics of women who developed ovarian hyperstimulation syndrome.  Hum Reprod. 2002;  17 1994-1996
• 37 Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS): Estradiol level has an important role in the prediction of OHSS.  Hum Reprod. 2003;  18 1140-1141
• 38 Thomas K, Searle T, Quinn A, Wood S, Lewis-Jones I, Kingsland C. The value of routine estradiol monitoring in assisted conception cycles.  Acta Obstetricia et Gynecologica Scandinavica. 2002;  81 551-554
• 39 Foong L C, Bhagavath B, Kumar J, Ng S C. Ovarian hyperstimulation syndrome is associated with reversible impairment of vascular reactivity.  Fertil Steril. 2002;  78 1159-1163
• 40 Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.  Fertil Steril. 1999;  71 808-814
• 41 Ho H Y, Lee R KK, Lin M H, Hwu Y M. Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation.  J Ass Reprod Gen. 2003;  20 222-226
• 42 Orvieto R, Leites T, Abir R, Bar J, Yoeli R, Feldberg D, Fisch B. Interleukin-2 production in whole blood cell cultures of women undergoing controlled ovarian hyperstimulation for assisted reproduction technology cycles.  AJRI. 2003;  50 220-223
• 43 Nakamura Y, Takasaki A, Sugino N, Tamura H, Takiguchi S, Takayama H, Harada A, Kato H. Studies on the effects of initial injection doses of follicle stimulating hormone on the pregnancy and the ovarian hyperstimulation syndrome incidence in polycystic ovarian syndrome patients.  Reprod Med Biol. 2003;  2 63-67
• 44 Ando H, Furugori K, Shibata D, Harata T, Murata Y, Mizutani S. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series.  Hum Reprod. 2003;  18 1219-1222
• 45 Ujioka T, Matsuura K, Tanaka N, Okamura H. Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model.  Hum Reprod. 1998;  13 3009-3015
• 46 Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF.  Acta Obstet Gynecol Scand. 2001;  80 452-466
• 47 Ludwig M, Doody K J, Doody K M. Use of recombinant human chorionic gonadotropin in ovulation induction.  Fertil Steril. 2003;  79 1051-1059
• 48 Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.  Fertil Steril. 2004;  81 1-5
• 49 McDonough P G. Vascular endothelial growth factor - mediator of OHSS?.  Fertil Steril. 2003;  79 1466-1467
• 50 Endo T, Honnma H, Hayashi T, Chida M, Yamazaki K, Kitajima Y, Azumaguchi A, Kamiya H, Kudo R. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos.  Hum Reprod. 2002;  17 2548-2551
• 51 Lainas T, Petsas G, Stavropoulou G, Alexopoulou E, Iliadis G, Minaretzis D. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization.  Fertil Steril. 2002;  78 529-533
• 52 Schröder A K, Schöpper B, Al-Hasani S, Diedrich K, Ludwig M. Unilateral follicular aspiration and in-vitro maturation before contralateral oocyte retrieval: a method to prevent ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 2003;  110 186-189
• 53 Evbuomvan I O, Davison J M, Baylis P H, Murdoch A P. Altered osmotic threshold for arginine vasopressin secretion and thirst during superovulation and in ovarian hyperstimulation syndrome (OHSS): relevance to pathophysiology of OHSS.  Fertil Steril. 2001;  75 933-941
• 54 Parsanezhad M E, Alborzi S, Pakniat M, Schmidt E H. A double-blind, randomized, placebo-controlled study to assess the efficacy of ketoconazole for reducing the risk of ovarian hyperstimulation syndrome.  Fertil Steril. 2003;  80 1151-1155
• 55 Amarin Z O. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome: An aggressive, but perhaps life-saving procedure.  Hum Reprod. 2003;  18 659-664
• 56 Bellver J, Escudero E, Pellicer A. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS): Ovarian mutilating surgery is not an option in the management of severe OHSS.  Hum Reprod. 2003;  18 1363-1367
• 57 Chen C D, Chao K H, Yang J H, Chen S U, Ho H N, Yang Y S. .  Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome Fertil Steril. 2003;  80 86-90
• 58 Avril C, Bastite L, Chaput-Toupin E, Villière J. Does ectrem obesity have an impact on ovarian response and outcome of infertile women included in IVF program.  Fertil Steril. 2003;  80 (Suppl 3) S178-179
• 59 Yarali H, Yildiz B O, Demirol A, Zeyneloglu H B, Yigit N, Bükülmez O, Koray Z. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.  Hum Reprod. 2002;  17 289-294
• 60 Kahraman S, Yakin K, Vanlioglu F, Donmez E, Karlikaya G, Yakup K. Metformin as an adjuvant therapy in patients with polycystic ovaries undergoing controlled ovarian stimulation.  Hum Reprod. 2003;  18 40 xviii-42 xviii, 115
• 61 Chang A S, Odem R R, Ratts V S. Addition of Metformin with gonadotropin stimulation in PCOS patients.  Fertil Steril. 2003;  80 (Suppl 3) 110-111
• 62 Vanlioglu F, Kahraman S, Karlikaya G, Karagozoglu H, Aygun M. Effect of metformin on subgroups pf patients with polycystic ovaries undergoing controlled ovarian stimulation for assisted reproduction.  Fertil Steril. 2003;  80 (Suppl 3) 111
• 63 Vanky E, Kjørød S B, Maesel A, Bjerve K S, Carlsen S M. Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome.  Fertil Steril. 2004;  81 459-462
• 64 Itskovitz-Eldor J, Kol S, Mannaerts B. Use of single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing controlled ovarian stimulation for assisted reproduction, with special refernce to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.  Hum Reprod. 2000;  15 1965-1968
• 65 Gomez R, Gonzalez M, Simon C, Remohi J, Pellicer A. Tyroxine hydroxylase (TH) downregulation in hyperstimulated ovaries reveals the dopamine agonist bromocriptine (Br2) as an effective and specific method to block increased vascular permeability (VP) in OHSS.  Fertil Steril. 2003;  80 43-44
• 66 Oelsner G, Cohen S B, Soriano D, Admon D, Mashiach S, Carp H. Minimal surgery for twisted ischaemic adnex can preserve ovarian function.  Hum Reprod. 2003;  18 2599-2602
• 67 Abramov Y, Fatum M, Abrahamov D, Schenker J G. Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report.  Fertil Steril. 2001;  75 1228-1230
• 68 Kissler S, Neidhardt B, Siebzehnrübl E, Schmitt H, Tschaikowsky K, Wildt L. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report.  Eur J Obstet Gynecol Reprod Biol. 2001;  99 131-134
• 69 Abuzeid M I, Nassar Z, Massaad Z, Weiss M, Ashraf M, Fakih M. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome.  Hum Reprod. 2003;  18 370-373
• 70 Al-Ramahi M, Leader A, Claman P, Spence. J First report of a pigtail catheter to drain ascites associated with OHSS.  Hum Reprod. 2003;  18 2235
• 71 Abuzeid M I. First report of a pigtail catheter to drain ascites associated with OHSS.  Hum Reprod. 2003;  18 2235-a
• 72 Dulitzky M, Cohen S B, Inbal A, Seidman D S, Sorianio D, Lidor A, Mashiach S, Rabinovici J. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome.  Fertil Steril. 2002;  77 463-467
• 73 Stewart J A, Hamilton P J, Murdoch A P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques.  Hum Reprod. 1997;  12 2167-2173
• 74 Arya R, Shehata H A, Patel R K, Sahu S, Rajasingam D, Harrington K F, Nelson-Piercy C, Parsons J H. Internal jugular vein thrombosis after assisted conception therapy.  Br J Haematol. 2001;  115 153-155
• 75 Stewart J A, Hamilton P J, Murdoch A P. Upper limb thrombosis associated with assisted conception treatment.  Hum Reprod. 1997;  12 2174-2175
• 76 Ulug U, Aksoy E, Erden H, Bayazit N, Bahçeci M. Bilateral internal jugular venous thrombosis following successful assisted conception in the absence of ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 2003;  109 231-233
• 77 McGowan B MC, Kay L A, Perry D J. Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization an a woman heterozygous for the prothrombin 3′UTR and factor V Leiden mutations.  Am J Hematol. 2003;  73 276-278
• 78 Ogawa S, Minakami H, ArakiI S, Ohno T, Motoyama M, Shibahara H, Sato I. Physiology: a rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome.  J Ass Reprod Gen. 2001;  18 114-119
• 79 Wiser A, Kreiser D, Levron J, Dor J, Schiff E, Shulman A. Outcome of pregnancies complicated by moderate and severe OHSS: a follow up beyond the second trimester.  Fertil Steril. 2003;  80 178
• 80 Van Nest R L, Stillman R J, Richter K S. Timing of presentation with severe OHSS predicts clinical IVF pregnancy.  Fertil Steril. 2003;  80 179
• 81 Tozer A J, Iles R K, Iammarrone E, Gillott C MY, Al-Shawaf T, Grudzinskas J G. The effects of ‘coasting’ on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome.  Hum Reprod. 2004;  DOI: 10.1093/humrep/deh096.1-7